Article

Bayer's Xofigo Gains NICE Approval

The National Institute for Health and Care Excellence has issued draft guidelines on using the drug in prostate cancer patients.

It is looking likely that patients with prostate cancer will, in certain circumstances, get ‘routine’ access to treatment with Bayer’s Xofigo (radium 223) on the National Health Service in England and Wales.

The National Institute for Health and Care Excellence has published draft guideline’s endorsing the drug as an option to treat adults with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases.

But this only extends to patients who have already been treated with docetaxel, and the recommendation is contingent upon on Bayer providing the drug with a confidential discount agreed in a patient access scheme.

Xofigo is a radio-pharmaceutical agent designed to directly deliver alpha radiation to bone metastases without affecting normal bone marrow. Bayer estimates the average cost for a six-month course with the drug (administered intravenously every four weeks) to be around £24,240.

Read the complete article on PharmaTimes: http://bit.ly/13tJUoI

Related Videos
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Rohan Garje, MD
Susan Escudier, MD, FACP
Sabarish Ayyappan, MD
Susan Escudier, MD, FACP
Screenshot of an interview with Evangelia Vlachou, MD
Screenshot of an interview with Barry Goy, MD
Debra Patt, MD, PhD, MBA, MPH
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo